Moving plasma Epstein-Barr virus (EBV) DNA load during follow-up periods predicts NPC recurrence and metastasis


For one study, researchers sought to investigate the kinetics of Epstein-Barr virus DNA (EBV DNA) and its effect on survival. A retrospective evaluation of 900 patients with nasopharyngeal carcinoma (NPC) was performed. At various times after treatment, plasma EBV DNA levels were examined. The relationship between EBV kinetics and recurrence and metastasis has been studied. After stratifying patients by EBV results, Kaplan-Meier estimates were used to compare survival. According to the EBV groups, benchmark analyzes at 12 and 24 months for overall survival (OS) data were performed. Patients with post-EBV counts below 2,500 copies/mL had a better chance of survival than those with higher counts. Additionally, patients with continuously elevated EBV DNA had significantly lower OS (relative risk [HR]2.542, 95% CI, 2.077–3.111; PPP= 0.013) and progression-free survival (HR, using the benchmark analyzes at 12 and 24 months, OS at 5 years with an increase in EBV was lower than in the remission group. After treatment, high concentrations of EBV DNA were a better predictor of survival than baseline amounts In addition, consistently elevated EBV DNA indicated recurrence, metastasis, and poor prognosis for NPC after treatment In addition, throughout from long-term follow-up, there were consistent patterns of EBV DNA kinetics, which require further investigation.


Comments are closed.